Methods of ameliorating symptoms of herpes infection using...

Details Methods of ameliorating symptoms of herpes infection using... Methods of ameliorating symptoms of herpes infection using...

2007-01-02

2007-01-02

Sullivan, Daniel M. (Department: 1636)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100

Reexamination Certificate

active

09802518

ABSTRACT:
The invention provides new methods of preventing and/or treating herpes virus infections, particularly reducing infection, one or more symptoms and recurrence of one or more symptoms of herpes simplex virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being posed to alphaherpesvirinae, has been exposed to alphaherpesvirinae or is infected with alphaherpesvirinae. The ISS is administered without any alphaherpesvirinae antigens. Administration of the ISS results in reduced incidence, recurrence, and severity of one or more symptoms of alphaherpesvirinae infection.

REFERENCES:
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4849513 (1989-07-01), Smith et al.
patent: 4910300 (1990-03-01), Urdea et al.
patent: 4948882 (1990-08-01), Ruth
patent: 5015733 (1991-05-01), Smith et al.
patent: 5093232 (1992-03-01), Urdea et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5616461 (1997-04-01), Schafer et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5874089 (1999-02-01), Schlegel et al.
patent: 6174872 (2001-01-01), Carson et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6498148 (2002-12-01), Raz
patent: 6514948 (2003-02-01), Raz et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 2001/0046967 (2001-11-01), Van Nest
patent: 2002/0028784 (2002-03-01), Nest
patent: 2002/0098199 (2002-07-01), Van Nest et al.
patent: 2002/0107212 (2002-08-01), Nest et al.
patent: 2003/0050263 (2003-03-01), Krieg et al.
patent: 2003/0216340 (2003-11-01), Van Nest et al.
patent: 2004/0009942 (2004-01-01), Van Nest
patent: 2004/0030118 (2004-02-01), Wagner et al.
patent: 2005/0059626 (2005-03-01), Van Nest et al.
patent: 468520 (1992-01-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55609 (1998-12-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 00/06588 (2000-02-01), None
patent: WO 00/16804 (2000-03-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO 00/62802 (2000-10-01), None
patent: WO 00/62802 (2000-10-01), None
patent: WO 00/67023 (2000-11-01), None
patent: WO 01/02007 (2001-01-01), None
patent: WO 01/12223 (2001-02-01), None
patent: WO 01/55341 (2001-08-01), None
patent: WO 01/55341 (2001-08-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO 01/68078 (2001-09-01), None
patent: WO 01/68078 (2001-09-01), None
patent: WO-01/68103 (2001-09-01), None
patent: WO-01/68103 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
patent: WO 01/68143 (2001-09-01), None
patent: WO 01/68143 (2001-09-01), None
patent: WO 01/68144 (2001-09-01), None
patent: WO 01/68144 (2001-09-01), None
patent: WO 01/76642 (2001-10-01), None
Tokunaga et al., How BCG led to the discovery of immunostimulatory DNA, 1999, Jpn. J. Infect. Dis., vol. 52, pp. 1-11.
Krieg, Direct immunologic activities of CpG DNA and implications for gene therapy, 1999, The Journal of Gene Medicine, vol. 1, pp. 56-63.
Verma et al., Gene therapy-promises, problems and prospects, 1997, NATURE, vol. 389, pp. 239-242.
Marshall, Gene therapy's growing pains, 1995, SCIENCE, vol. 269, pp. 1050-1055.
Orkin et al., Report and recommendations of the panel to assess the NIH investment in research on gene therapy, 1995, NIH.
Mountain, Gene therapy: the first decade, 2000, TIBTECH, vol. 18, pp. 119-128.
Kmiec, Gene therapy, 1999,American Scientist, vol. 87, pp. 240-247.
Weiner et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. Sep. 30, 1997;94(20):10833-7.
Hartmann et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. Feb. 1, 2000;164(3):1617-24.
Pyles et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. nJ Virol. Nov. 2002;76(22):11387-96.
Rosenthal et al. Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis. Feb. 1997;24(2):135-9.
Ausubel, Fredrick M. et al., eds. (1995).Current Protocols in Molecular Biology. vol. 1, John Wiley & Sons, Inc.: pp. iii-xii (Table of Contents).
Ballus, Zuhair et al. (1996). “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA”J. Immunol.157:1840-1845.
Beaucage, Sarge L. (1993). “Oligodeoxyribonucleotide Synthesis” vol. 20 Chapter 2in Protocols for Oligonucleotides and Analogs, Synthesis and Properties, Agrawal (ed.), Humana Press: Totowa, NJ. pp. 33-61.
Bourne, Nigel et al. (1996). “DNA Immunization Against Experimental Genital Herpes Simplex Virus Infection”J. Infest. Dis.173(4):800-807.
Bourne, Nigel et al. (1996). “DNA Immunization Confers Protective Immunity on Mice Challenged Intravaginally with Herpes Simplex Virus Type 2”Vaccine14(13):1230-1234.
Branda, Richard F. et al. (1993). “Immune Stimulation by an Antisense Oligomer Complementary to the Rev Gene of HIV-1”Biochem. Pharmacol.45(10):2037-2043.
Branda, Richard F. et al. (1996). “Amplification of Antibody Production by Phosphorothioate Oligodeoxynucleotides”J. Lab. Clin. Med.128(3):329-338.
Braun, Ralph P. and Lee, Jeremy S. (1998). “Immunogenic Duplex Nucleic Acids are Nuclease Resistant” J. Immunol. 141(6):2084-2089.
Brazolot Millan, Cynthia L. et al. (1998). “CpG DNA can Induce Strong Th1 Humoral and Cell-Mediated Immune Responses Against Hepatitis B Surface Antigen in Young Mice”Proc. Natl. Acad. Sci. USA95:15553-15558.
Broide, David et al. (1998). “Immunostimulatory DNA Sequences Inhibit IL-5, Eosinophilic Inflammation, and Airway Hyperresponsiveness in Mice”J. Immunol.161:7054-7062.
Broide, David and Raz, Eyal (1999). “DNA-Based Immunization for Asthma”Int. Arch. Allergy Immunol.118:453-456.
Burke, Rae Lyn et al. (1994). “Influence of Adjuvant on the Therapeutic Efficacy of a Recombinant Genital Herpes Vaccine”J. Infect. Dis.170:1110-1119.
Carson, Dennis A. and Raz, Eyal (1997). “Oligonucleotide Adjuvants for T Helper 1 (Th1)-Specific Vaccination”J. Exp. Med.186(10):1621-1622.
Chace, Jacqueline H. et al. (1997). “Bacterial DNA-Induced NK Cell IFN-Gamma Production is Dependent on Macrophage Secretion of IL-12”Clin. Immunol. and Immunopathol.84(2):185-193.
Chaturvedi, Surendra et al. (1996). “Stabilization of Triple-Stranded Oligonucleotide Complexes: Use of Probes Containing Alternating Phosphodiester and Stereo-Uniform Cationic Phosphoramidate Linkages”Nucleic Acids Res.24(12):2318-2323.
Chu, Rose S. e

Affiliated with

Also associated with

Rating

Methods of ameliorating symptoms of herpes infection using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of ameliorating symptoms of herpes infection using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of ameliorating symptoms of herpes infection using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3731338